New targets for antipsychotics

Expert Review of Neurotherapeutics

Volumn 2, Issue 1, 2002, Pages 61-68

  Jones, Hugh M ^a   Pilowsky, Lyn S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Dopamine; NMDA; Pharmacogenetics; Receptors; Schizophrenia; Serotonin

Indexed keywords

ADROGOLIDE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; CLOZAPINE; DEXTRO SERINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR AGONIST; GLYCINE; HALOPERIDOL; MIANSERIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RITANSERIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

AKATHISIA; AMNESIA; CATALEPSY; DRUG ACTIVITY; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; NEUROTOXICITY; PHARMACOGENOMICS; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; WORKING MEMORY;

EID: 0036283366     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.1.61     Document Type: Review

References (91)

1. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
2. Agranulocytosis In patients treated with clozapine. A study of the Finnish epidemic
3. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis
4. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials
5. Overview of efficacy of atypical antipsychotics in treatment resistant schizophrenia. 5 Robinson DG, Woerner MG, Alvir J et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder
6. McGorry PD. Preventing severe mental illnesses-new prospects and ethical challenges
7. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
8. Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histaminergic receptors to clinical potency
9. Antipsychotic drug doses and neuroleptic/dopamine receptors
10. Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia
11. D 1 and D2 dopamine receptor occupancy with conventional and atypical neuroleptics
12. Kerwin RW. Antipsychotic medication, D2 receptor blockade and clinical response- a 123I-IBZM single photon emission tomography study
13. Dopamine blockade and clinical response; evidence for two biological subgroups of schizophrenia
14. Clozapine, single photon emission tomography and the D 2 dopamine receptor hypothesis of schizophrenia
15. Single photon emission tomography imaging of amphetamine induced dopamine release in drug free schizophrenic subjects
16. Relationship between dopamine D2 occupancy, clinical response and side effects: A double-blind PET study of first episode schizophrenia
17. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients
18. Limbic selectivity of clozapine
19. Extrastriatal and striatal D 2 dopamine receptor blockade with haloperidol or new antipsychotics in patients with schizophrenia
20. The action of quetiapine at striatal and extrastriatal D2/D 3 receptors in vivo
21. The cerebral cortex: Case for a common site of action of antipsychotics
22. Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects
23. No support for regional selectivity in clozapine treated patients: A PET study with [11C] raclopride and [11C] FLB 457
24. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia
25. A positron emission tomography study of quetiapine in schizophrenia
26. Cloning of the gene for the human dopamine D 4 receptor with high affinity for the antipsychotic clozapine
27. Placebo-controlled study of the D4/5-HT 2A antagonist fananserin in the treatment of schizophrenia
28. Palacios JM. Dopamine D 3 receptor mRNA and binding sites in human brain
29. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D 2 expressing neurons
30. Dopamine D3 rceptor: Basic and clinical aspects
31. Pharmacologic actions of a novel, high-affinity and selective dopamine D3 receptor antagonist, SB-277011-A
32. Effect of apomorphine on schizophrenic symptoms
33. Treatment of schizophrenia with ergot derivatives
34. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxylphenyl)-N-n-Propylpiperidine (Preclamol) in schizophrenia
35. Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives
36. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain
37. A common action of clozapine, haloperidol and remoxipride on D1- and D2-dopaminergic transmission in the primate cerebral cortex
38. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D 1 receptor stimulation
39. Lack of apparent antipsychotic effect of the D 1 dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients
40. New drugs for the treatment of schizophrenia
41. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
42. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
43. A biological and pharmacological suggestion about certain mental disorders
44. Hallucinogenic drug interactions with neurottansmirter receptor binding sites in human cortex
45. Thymosthenic agents, a novel approach in the treatment of schizophrenia
46. Ritanserin a selective 5-HT2/1C antagonist and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
47. i values
48. 1A receptor activation: A possible mechanism of atypical antipsychotic induced cortical dopamine release
49. An overview of the mechanism of action of clozapine
50. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat. An in vivo microdialysis study
51. Serotonin-Dopamine interactions in the nigrostiatal system
52. Serotonin - Dopamine interaction and its relevance to schizophrenia
53. Clozapine is a partial agonist at cloned human serotonin 5-HT 1A receptors
54. Serotonin receptors in the human brain-IV Autoradiographic mapping of serotonin- 2 receptors
55. Inncrease in serotonin 5-HT 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia
56. The 5-HT1A receptor: A promising target for novel atypical neuroleptics?
57. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
58. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study
59. 2C receptor antagonist
60. SB-242084, a selective serotonin 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system
61. 3 mediated control of dopaminergic function
62. Clozapine blocks dopamine, 5-HT2 and 5-HT3 responses in the medial prefrontal cortex: An in vivo microiontophoretic study
63. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT 3 receptor antagonists
64. Glutamate Receptor expression in schizophrenic brain
65. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus; effects of schizophrenia
66. Recent advances in the phenylcyclidine model of schizophrenia
67. Study of a new schizophrenomimetic drug - Sernyl
68. Effect of phenylcyclidine in chronic schizophrenia
69. Modulation of N-methyl-D-aspartate receptor function by glycine transport
70. Amelioration of negative symptoms in schizophrenia by glcine
71. Eficacy of high dose glycine in the treatment of enduring negative symptoms of schizophrenia
72. D-serine added to antipsychotics for the treatment of schizophrenia
73. Analysis of the initial treatment phase in first-episode psychosis
74. The development of treatment resistance in patients with schizophrenia: A clinical and pathophysiologic perspective
75. The profiles of clinical deterioration in schizophrenia
76. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective
77. Rationale for study of early intervention
78. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?
79. Risperidone in the treatment of first episode psychotic patients: A double-blind multicenter study. Risperidone Working Group
80. Identification of young people at risk of psychosis: Validation of personal assessment and crisis evaluation clinic intake criteria
81. Plasma clozapine concentrations predict clinical response in treatment resistant schizophrenia
82. Functional significance of a C - A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
83. The clinical use of plasma clozapine levels
84. 2A receptors and clozapine response
85. Pharmacogenetic prediction of clozapine response
86. A targeted mutation of the D 3 dopamine receptor gene is associated with hyperactivity in mice
87. Pharmacogenetic assessment of antipsychotic-induced movement disorders: Contribution of the dopamine D3 receptor and cytochrome P450 IA2 genes
88. Genetic DISsection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle
89. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
90. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia
91. Neuroleptics and the natural course of schizophrenia